Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.

Notably, when the patients were classified by ORR into a complete response (CR)/partial response (PR) group, a stable disease (SD) group, and progressive disease (PD) group, the CR/PR group contained a higher proportion of patients in the low-risk group, although these differences did not reach statistical significance ( Figure S4D ).

also in 111,027 other papers